Lipocine announces presentations at the international liver congress™ 2021 digital event

Salt lake city, june 23, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at the international liver congress™ 2021, the annual meeting of the european association for the study of the liver ("easl"), digital event, on june 23-26, 2021.  1.
LPCN Ratings Summary
LPCN Quant Ranking